News & Analysis as of

Life Sciences Startups Investment Opportunities

Wilson Sonsini Goodrich & Rosati

[Event] Biotech Summit 2024 - October 9th - 10th, Boston, MA

Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more

Wilson Sonsini Goodrich & Rosati

[Event] Medical Device Digital Health Conference - June 13th - 14th, San Francisco, CA

Wilson Sonsini’s 31st Annual Medical Device & Digital Health Conference will address topics of critical importance to medical device and digital health companies, including early and late-stage venture financing, partnering...more

Fenwick & West Life Sciences Group

New Funding Cycle for Digital Health Begins on Cautious Note

For digital health startups, the first two months of this year were a welcome departure from 2022, when high inflation and other economic challenges caused investors to press on the brakes and proceed with caution....more

Fenwick & West LLP

Life Sciences Summit: Biotech IPO Market Shows Signs of Life

Fenwick & West LLP on

As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next?  Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more

Fenwick & West Life Sciences Group

Market Slowdown is Opportunity for Digital Health Companies to Hone Focus, Deliver Bold Yet Tenable Plans

There are more investors in digital health today than there have ever been, but the questions they are posing to company founders before writing a check are tougher than they were just a year ago....more

Fenwick & West Life Sciences Group

Digital Health Has Strong Fundamentals to Pull Through Downturn

Digital health has been a powerhouse investment sector since it emerged more than a decade ago. Year-after-year, startups consistently demonstrate their innovations bring real-world benefits and our healthcare system...more

Fenwick & West Life Sciences Group

Big Tech Continues Foray Into Healthcare, Opening New Opportunities for Digital Health Startups

As the financial markets continue to struggle, digital health companies are conserving resources, slowing hiring and minding their burn rate given the uncertainty around the current economic slowdown and whether the economy...more

Fenwick & West Life Sciences Group

Digital Health Faced Headwinds in the First Quarter of 2022

Investors are understandably cautious this year as the Federal Reserve tightens monetary policies and financial markets erased the gains from the last 12 months. Public company investors in sectors with enticing upside—like...more

Fenwick & West Life Sciences Group

Economic Conditions Changing, but Digital Health Still Strong

The digital health sector emerged as a juggernaut during the COVID-19 pandemic, with almost $15 billion invested in privately-held digital health companies in 2020 and nearly $30 billion invested last year, according to our...more

Fenwick & West Life Sciences Group

Rock Health Summit Brings Together Brightest Minds in Digital Health

In the technology sector, entrepreneurs are often told to “move fast and break things.” But breaking things is something that won’t work in healthcare, so, as an alternative, innovators may consider “moving fast and keeping...more

Fenwick & West Life Sciences Group

Life Sciences IPOs, SPACs on the Upswing in H1 2021

Public market investors have offered a warm welcome to life sciences companies so far in 2021. As Fenwick’s recent H1 2021 Going Public Report shows, the pace has picked up as 2021 progresses, with 31 life sciences IPOs in...more

Fenwick & West Life Sciences Group

Midway Through 2021, Digital Health Startups Sprint Past 2020 Records

At the end of Q1 2021, our friends at Rock Health noted the record-breaking $6.7 billion raised by digital health startups and declared the sector “all grown up.” The additional $8 billion raised in the second quarter of this...more

Fenwick & West Life Sciences Group

IPO Life Sciences Outlook: COVID-19 Vaccine Innovation Could Boost IPO Numbers to Another Record High

The life sciences sector will likely be one of the major drivers in what some analysts predict as the beginning of the largest economic expansion in recent history. ...more

Fenwick & West Life Sciences Group

Digital Health IPO Class of 2020: How Are They Performing Now?

In prior years, it was almost a foregone conclusion that promising digital health startups would be acquired by other companies before having the opportunity to debut on the public markets. However, that changed in 2019,...more

Fenwick & West Life Sciences Group

Digital Health Investors Offer Cautious Optimism at Rock Health H1 2020 Event

Venture investors are pleased to see digital health companies continue to transform the healthcare system despite unprecedented challenges brought by the COVID-19 pandemic....more

Fenwick & West Life Sciences Group

Digital Health Investments See Significant Uptick in Q1; Investors Consider COVID-19 Impacts in Coming Months

Despite the changes and uncertainty rippling across the entire venture-backed startup ecosystem, the digital health sector saw its best first quarter since analysts began tracking its performance more than a decade ago,...more

Fenwick & West Life Sciences Group

Key Takeaways from Fenwick’s 2019 Digital Health Investor Summit

Fenwick’s eighth annual Digital Health Investor Summit took place against the backdrop of strong and increasingly diverse investment markets, a focus on clinical validation of digital health tools, and a healthcare system...more

McDermott Will & Emery

[Event] 2019 Venture Capital Investing Bootcamp - October 15th-16th, Cambridge, MA

McDermott Will & Emery on

LIFE SCIENCES VC INVESTING BOOTCAMP - Exclusively open to venture capital investment professionals, this training program is dedicated to the critical due diligence, IP, regulatory, reimbursement and transactional issues...more

Fenwick & West Life Sciences Group

Divestitures and Consolidation in Animal Health Market Present Opportunities to Investors, Innovators

The business of animal health has traditionally been dominated by the animal health divisions of big pharma companies. But with Pfizer’s 2013 spin-off of its animal health business, now known as Zoetis, the sector has been...more

19 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide